Brief: Ascletis Announces Ind Filing Of Its Second Fasn Inhibitor Asc60 For Advanced Solid Tumors Accepted By China Nmpa
26/01/2022 11:15
Jan 26 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASCLETIS ANNOUNCES IND FILING OF ITS SECOND FASN INHIBITOR
ASC60
FOR ADVANCED SOLID TUMORS ACCEPTED BY CHINA NMPA
Source text for Eikon: ID:nPn8qTcxa
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026